DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS

被引：0
|
作者：
Zannoni, L. [1 ]
Forte, D. [1 ]
Sartor, C. [1 ]
Cristiano, G. [1 ]
Nanni, J. [1 ]
Parisi, S. [2 ]
Zingarelli, F. [1 ]
Bandini, L. [1 ]
Testoni, N. [1 ]
Ottaviani, E. [2 ]
Paolini, S. [2 ]
Papayannidis, C. [2 ]
Cavo, M. [1 ,3 ]
Rutella, S. [3 ]
Curti, A. [2 ]
机构：
[1] Univ Bologna, Dipartimento Sci Med Chirurg, Bologna, Italy
[2] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy
[3] Nottingham Trent Univ, John Geest Canc Res Ctr, Nottingham, England
来源：
HAEMATOLOGICA | 2024年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P033
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [31] Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Xia, Leiming
    Tian, Wanlu
    Zhao, Yiming
    Jiang, Lingling
    Qian, Wei
    Jiang, Lei
    Ge, Ling
    Li, Jianjun
    Jin, Fengbo
    Yang, Mingzhen
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [32] Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Leiming Xia
    Wanlu Tian
    Yiming Zhao
    Lingling Jiang
    Wei Qian
    Lei Jiang
    Ling Ge
    Jianjun Li
    Fengbo Jin
    Mingzhen Yang
    Signal Transduction and Targeted Therapy, 8
  • [33] A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
    Fathi, Amir T.
    Fell, Geoffrey G.
    El-Jawahri, Areej
    Perl, Alexander E.
    Jonas, Brian A.
    Dias, Ajoy L.
    Mims, Alice S.
    Borate, Uma
    Ragon, Brittany Knick
    Grunwald, Michael R.
    Peters, Mary Linton B.
    Graubert, Timothy A.
    Amrein, Philip C.
    Hock, Hanno R.
    Brunner, Andrew M.
    Hobbs, Gabriela S.
    Narayan, Rupa
    Neuberg, Donna S.
    Aldoss, Ibrahim
    BLOOD, 2022, 140 : 3284 - 3286
  • [34] COST-EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH AZACITIDINE IN UNFIT PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA IN CHINA
    Wu, Y.
    Xu, H.
    Zhao, X.
    Hong, G.
    Liu, J.
    Yang, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S132 - S132
  • [35] Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
    Chen, Tzu-Ting
    Lin, Ching-Chan
    Lo, Wen-Jyi
    Hsieh, Ching-Yun
    Lein, Ming-Yu
    Lin, Che-Hung
    Lin, Chen-Yuan
    Bai, Li-Yuan
    Chiu, Chang-Fang
    Yeh, Su-Peng
    CANCERS, 2024, 16 (06)
  • [36] COSTS PER RESPONDER WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE IN UNFIT PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA IN CHINA
    Xu, H.
    Zhao, X.
    Mo, X.
    Zhao, J.
    Liu, J.
    Yang, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S152 - S152
  • [37] Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
    Liu, Qingyang
    Yang, Jingjing
    Lv, Lei
    Zhang, Xiawei
    Li, Meng
    Xu, Lingmin
    Huang, Sai
    Jing, Yu
    Dou, Liping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [38] Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia
    Gil, Kellen B.
    Abbott, Diana
    Amaya, Maria L.
    Schwartz, Marc
    Gutman, Jonathan A.
    Kent, Andrew
    Bosma, Grace
    Pollyea, Daniel A.
    McMahon, Christine M.
    LEUKEMIA & LYMPHOMA, 2024, 65 (14) : 2228 - 2230
  • [39] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
    Doyel, Michael
    Bouligny, Ian Michael
    Murray, Graeme
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Thuy Ho
    Zacholski, Kyle
    Venn, Chad Michael
    Alnimer, Yanal Mufeed
    Wages, Nolan
    Grant, Steven
    Maher, Keri Renee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis
    Guinan, Kimberly
    Mathurin, Karine
    Au, Yunghan
    Schuh, Andre C.
    Bui, Cat N.
    Chai, Xinglei
    Lachaine, Jean
    CURRENT ONCOLOGY, 2022, 29 (10) : 7524 - 7536
12345